DESTINY PHARMA PLC
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 15
- Market Cap
- -
- Website
- http://www.destinypharma.com
Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection
Phase 2
Completed
- Conditions
- Staphylococcal InfectionsSurgical Site Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Destiny Pharma Plc
- Target Recruit Count
- 124
- Registration Number
- NCT03915470
- Locations
- 🇺🇸
CHI Franciscan Research Center, Tacoma, Washington, United States
🇷🇸Clinical Center Nis, Niš, Serbia
🇺🇸University of Missouri Health Care, Columbia, Missouri, United States
Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Destiny Pharma Plc
- Target Recruit Count
- 12
- Registration Number
- NCT02284555
- Locations
- 🇬🇧
Simbec Reseach Ltd, Wales, United Kingdom
Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
Phase 1
Completed
- Conditions
- Staphylococcus Aureus Infection
- Interventions
- Drug: XF-73 nasal gelDrug: Placebo nasal gelOther: Chlorhexidine gluconate 2% topical cloths
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Destiny Pharma Plc
- Target Recruit Count
- 60
- Registration Number
- NCT02282605
- Locations
- 🇬🇧
Quintiles Drug Research Unit, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath